Brooke-Spiegler Syndrome : Two Patients From a Turkish Family With Multiple Familial Trichoepithelioma by Gunes, Cakmak Genc et al.
LETTERS TO THE EDITOR
Brooke–Spiegler Syn-
drome: Two Patients
From a Turkish Family
With Multiple Familial
Trichoepithelioma
To the Editor:
Brooke–Spiegler syndrome
(BSS) is a rare hereditary autosomal
dominant disease. It is characterized by
multiple benign skin appendageal tu-
mors such as cylindromas, trichoepi-
theliomas, and spiradenomas. Familial
cylindromatosis (FC) and multiple
familial trichoepithelioma (MFT) are
phenotypic variants of BSS. FC is
characterized by cylindromas and MFT
by trichoepitheliomas as the only tumor
type. The cylindromatosis gene (CYLD)
is the causative gene responsible for the
development of BSS and its phenotypic
variants. The CYLD is a tumor sup-
pressor gene that plays a key role on
regulation of NF-kB signaling path-
way.1 In this study, we present 2 cases
in a Turkish family with MFT carrying
the CYLD mutation and aim to discuss
with the literature.
The case of 53-year-old male
patient was referred to our clinic by the
Plastic Surgery Department. The patient
had a 25-year long history of multiple
lesions on his face, which appeared in
adolescence and slowly had been grow-
ing in sizes and numbers during the
following years. Clinical examination
showed the patient had numerous pap-
ules and nodules with ranging in size
from 1 · 1 to 2 · 2 cm on the face
mostly around the nose, periorbital area,
and ears (Fig. 1). To date, results of all
biopsies have supported the diagnosis of
trichoepithelioma. In addition, basal cell
carcinoma (BCC) has been determined
in the last 2 histopathological examina-
tions (Figs. 2 and 3).
The 19-year-old daughter of the
proband also presented similar lesions
but were fewer in number on her fore-
head, nasolabial, postauricular, and
occipital regions. Her nodular and pap-
ular lesions began 8 years ago and most
of them had been removed for esthetical
FIGURE 1. Clinical data of family with BSS. A–C, Multiple papules on the proband’s face, mostly around the nose, periorbital area,
and ears. D, Pedigree of the family.
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reasons. Histopathological examinations
of the lesions revealed trichoepithelio-
ma. Pedigree analysis of the family is
consistent and an autosomal dominant
inheritance (Fig. 1).
The genetic investigations were
conducted on the peripheral blood sam-
ples of the patients. From the blood
sample, genomic DNA was isolated and
the coding regions, and the ﬂanking
introns of the CYLD gene were ampliﬁed
with speciﬁc primers. The polymerase
chain reaction products were sequenced
using ABI Prism 7000 sequencer.
Our investigations have been iden-
tiﬁed a heterozygous nonsense mutation
(c.2104delA, p.Ile702X) in the 15th exon
of the CYLD gene in 2 patients. The pres-
ence of the mutation leads to the formation
of premature stop codon and thus to the
synthesis of a truncated CYLD protein.
Until now, more than 90 muta-
tions have been identiﬁed for the CYLD
gene in individuals presented with the
phenotypic characteristics of BSS, FC,
and/or MFT in the literature. The most
of reported CYLD mutations cause
premature protein truncations. First,
a germline CYLD mutation is inherited,
and second, noninherited CYLD muta-
tion or loss of heterozygosity occurs in
cells for tumor formation in BSS.2,3
The c.2104delA, p.Ile702X muta-
tion has been described only once in the
mother and daughter by Sima et al.4 Our
patients had clinically and histopatholog-
ically diagnosed MFT, whereas their pa-
tients had multiple scalp tumors and
histopathologically diagnosed cylindro-
mas.4 The comparisons of mutations
and clinical variations have revealed that
FIGURE 2. Trichoepithelioma. A, Hematoxylin eosin ·100. Nests of basaloid cells, some with abortive hair follicle differentiation.
B, Hematoxylin eosin ·200. Another lesion of the same case. Basaloid lobules showing prominent keratocysts and infundibular
keratinization (arrow) without epidermal continuity, retraction artifact, or stromal mucin.
FIGURE 3. Hematoxylin eosin ·200. Basal cell carcinoma. Basaloid lobules showing
peripheral palisading (white arrows) and retraction artifact (blue arrows) accompa-
nied with stromal mucin (red arrows) and epidermal ulceration (black arrow).
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the nonsense mutations are associated
with the highest phenotypic diversity
and recurrence rate, whereas missense
mutations are associated with trichoepi-
theliomas and a milder phenotype. But,
a clear genotype–phenotype correlation
is currently unknown.5,6
Also BCC has been determined in
our patient.As far asweknow, theBCChas
been reported for the ﬁrst time with
c.2104delA, p.Ile702X mutation. Trichoe-
pitheliomas are typically benign but rarely
develops BCC in patients affected with
MFT. However, CYLD is important in
more common cancers such as colorectal,
hepatocellular carcinoma, and melanoma.7
Consequently, our report supports
the view that there is a lack of genotype–
phenotype correlation. In addition, the
inability to establish genotype–
phenotype correlation suggests different
changes such as secondary epigenetic
events downstream besides the CYLD
mutations. Further studies to conﬁrm
these arguments will be helpful in elu-
cidating the mechanism leading to phe-
notypic differences observed in patients
carrying the same mutations. Better
understanding of the molecular mecha-
nisms of CYLD and BSS may help to
identify new treatment options. Fur-
thermore, physicians should be aware of
the potential for the development of
BCC despite commonly benign clinical
presentation. Long-term follow-up of the
patients will be crucial to the early diag-
nosis of malignancies.
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